PAVmed Inc. operates as a medical device company in the United States. More Details
Excellent balance sheet with weak fundamentals.
Share Price & News
How has PAVmed's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: PAVM is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.
Volatility Over Time: PAVM's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
Return vs Industry: PAVM exceeded the US Medical Equipment industry which returned 34.1% over the past year.
Return vs Market: PAVM exceeded the US Market which returned 39.4% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is PAVmed's share price compared to the market and industry in the last 5 years?
Simply Wall St News
Is PAVmed undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate PAVM's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate PAVM's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: PAVM is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.
PE vs Market: PAVM is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate PAVM's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: PAVM is overvalued based on its PB Ratio (10.9x) compared to the US Medical Equipment industry average (4.7x).
How is PAVmed forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PAVM is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: PAVM is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: PAVM is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if PAVM's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if PAVM's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if PAVM's Return on Equity is forecast to be high in 3 years time
How has PAVmed performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PAVM is currently unprofitable.
Growing Profit Margin: PAVM is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: PAVM is unprofitable, and losses have increased over the past 5 years at a rate of 37.7% per year.
Accelerating Growth: Unable to compare PAVM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PAVM is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (11.1%).
Return on Equity
High ROE: PAVM has a negative Return on Equity (-64.71%), as it is currently unprofitable.
How is PAVmed's financial position?
Financial Position Analysis
Short Term Liabilities: PAVM's short term assets ($50.5M) exceed its short term liabilities ($3.3M).
Long Term Liabilities: PAVM has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: PAVM's debt to equity ratio (0.6%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if PAVM's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: PAVM has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: PAVM has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of 39.8% each year.
What is PAVmed current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate PAVM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate PAVM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PAVM's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PAVM's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of PAVM's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Lishan Aklog (54 yo)
Dr. Lishan Aklog, M.D, serves as Director at ContraFect Corporation since June 14, 2020. Dr. Aklog has also served as Executive Chairman of Lucid Diagnostics Inc. since its inception in 2018. Dr. Aklog ser...
CEO Compensation Analysis
Compensation vs Market: Lishan's total compensation ($USD1.20M) is about average for companies of similar size in the US market ($USD1.66M).
Compensation vs Earnings: Lishan's compensation has increased whilst the company is unprofitable.
Experienced Management: PAVM's management team is considered experienced (4.8 years average tenure).
Experienced Board: PAVM's board of directors are considered experienced (6.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 76.7%.
PAVmed Inc.'s company bio, employee growth, exchange listings and data sources
- Name: PAVmed Inc.
- Ticker: PAVM
- Exchange: NasdaqCM
- Founded: 2014
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$537.601m
- Shares outstanding: 83.87m
- Website: https://www.pavmed.com
Number of Employees
- PAVmed Inc.
- One Grand Central Place
- Suite 4600
- New York
- New York
- United States
PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell col...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/06/19 07:03|
|End of Day Share Price||2021/06/18 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.